Lamivudine Teva Pharma (Lamivudine)

Lamivudine is taken up by cells and phosphorylated to its active triphosphate form. This active metabolite competes with natural nucleosides for incorporation into viral DNA by reverse transcriptase. Because lamivudine lacks a 3′‑hydroxyl group, its incorporation terminates the DNA chain, halting replication of HIV and hepatitis B virus.

The appropriate lamivudine dose is individualized by the prescribing healthcare professional based on the specific indication, patient weight, renal function, and whether it is used in combination with other antiretrovirals. Patients should follow the dose prescribed by their clinician.

Safety data for lamivudine in pregnancy are limited, and the pregnancy category is listed as unknown. It may be used only when the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding decisions should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other NRTIs or agents from different classes for synergistic effect. Compared with older NRTIs, lamivudine generally has a favorable tolerability profile and a lower incidence of mitochondrial toxicity, though drug‑specific interactions must still be considered.

Lamivudine tablets should be stored at temperatures below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid exposure to excessive heat or humidity, which could affect tablet integrity.

Lamivudine is administered orally, usually as a tablet taken with or without food. The exact dosing schedule and whether it is taken once or twice daily are determined by the prescribing clinician based on the therapeutic indication and patient-specific factors.

Serious adverse events, although rare, include lactic acidosis, severe hepatomegaly with steatosis, and pancreatitis. These conditions require immediate medical attention. Patients should be monitored regularly for signs of metabolic disturbances, liver enlargement, or abdominal pain.

Lamivudine should be avoided in individuals with a known hypersensitivity to lamivudine or any other nucleoside reverse transcriptase inhibitor. Caution is also advised for patients with severe renal impairment, active liver disease, or those taking medications that have major interaction risks.